Prolactin and oxytocin interaction in the paraventricular and supraoptic nuclei: effects on oxytocin mRNA and nitric oxide synthase.
We investigated the contribution of prolactin and oxytocin to the increase in staining for NADPH-d and oxytocin mRNA in the paraventricular nucleus (PVN) and supraoptic nucleus (SON) observed at the end of pregnancy, or following a steroid-priming regimen that mimics the hormonal profile of late pregnant females. Ovariectomized rats received chronic implants of silastic capsules containing oestrogen and progesterone followed by progesterone removal. In experiment 1, oxytocin antagonist (OTA) was administered to rats to investigate whether intranuclear oxytocin release was necessary for NADPH-d staining. In experiments 2a and b, rats received concurrent treatment with bromocryptine (0.5 mg/day) to suppress endogenous prolactin release, and either systemic prolactin (0.5 mg once daily), or prolactin (2 micro g/ micro l), or vehicle infused twice a day into the third ventricle, or chronic oxytocin infusion (24 ng/day) for 3 days following progesterone removal. Brains were then processed for NADPH-d histochemistry. In experiment 3, the interaction of prolactin and oxytocin on oxytocin mRNA within the SON and PVN was examined. NADPH-d staining in the SON and PVN was reduced by the highest dose of the OTA, and by bromocryptine treatment. Central prolactin and oxytocin replacement completely restored NADPH-d staining in bromocryptine-treated rats. Finally, both bromocryptine and the OTA suppressed oxytocin mRNA expression and prolactin replacement restored expression levels to that of controls. Together, these data suggest that the increased capacity to produce nitric oxide in the SON and PVN during late pregnancy is dependent on prolactin stimulating oxytocin gene mRNA and hence intranuclear oxytocin release.
Popeski
N
N
Center for Studies in Behavioral Neurobiology, Psychology Department, Concordia University, Montreal, Quebec, Canada.
Amir
S
S
Diorio
J
J
Woodside
B
B
D000818:Animals; D001971:Bromocriptine / Q000494:pharmacology; D004343:Drug Implants; D004347:Drug Interactions; D004967:Estrogens / Q000008:administration & dosage; D005260:Female; D006651:Histocytochemistry; D009252:NADPH Dehydrogenase / Q000032:analysis; D019001:Nitric Oxide Synthase / Q000378:metabolism*; D010052:Ovariectomy; D010121:Oxytocin / Q000008:administration & dosage* / Q000037:antagonists & inhibitors / Q000235:genetics; D010286:Paraventricular Hypothalamic Nucleus / Q000737:chemistry / Q000378:metabolism*; D011247:Pregnancy; D011374:Progesterone / Q000008:administration & dosage; D011388:Prolactin / Q000008:administration & dosage* / Q000037:antagonists & inhibitors / Q000502:physiology; D012333:RNA, Messenger / Q000032:analysis; D051381:Rats; D013495:Supraoptic Nucleus / Q000737:chemistry / Q000378:metabolism*
D004343:Drug Implants; D004967:Estrogens; D012333:RNA, Messenger; D001971:Bromocriptine; D011374:Progesterone; D010121:Oxytocin; D011388:Prolactin; D019001:Nitric Oxide Synthase; D009252:NADPH Dehydrogenase